✉news HealthFitness first seen 16 h ago, last 14 h ago, peak #17
CSL may spend up to $2.2 billion on Swiss biotech deal
Original: CSL could spend up to $2.2b on drug deal with Swiss biotech start-up
Australian biotech giant CSL is reported to be weighing a deal worth up to $2.2 billion with a Swiss biotech start-up, according to the Australian Financial Review. The arrangement would centre on rights to a drug candidate, adding to CSL's pipeline as it looks for new growth areas beyond its established plasma-based therapies.
Why now: The size of the potential investment and CSL's search for pipeline growth make the reported deal newsworthy for investors and the biotech sector.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/1074291